ANAB logo

ANAB AnaptysBio, Inc.

NASDAQ · Biotechnology · Healthcare

$46.63
-0.77 (-1.62%)

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial …

Market Cap: $1.39Bwww.anaptysbio.com

Price

No data yet.

Social Signal Score

54
5d
70
1 mentions
—
30d
50
4 mentions
—
60d
50
4 mentions
—
90d
47
6 mentions
—
news: 6

Analyst Ratings

23 analysts
Buyconsensus
Strong Buy 0Buy 17Hold 6Sell 0Strong Sell 0
Avg price target$81+73.7%
Low $70Median $79.5High $95
Current Consensus

Revenue

$30.27M+999.27%
$0.00$36.08M$72.17M$108.25M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-0.96
$-2.11–$-0.29
8 analysts
FY2026
$4.51
$4.05–$4.89
1 analysts
FY2027
$7.50+66% YoY
$6.73–$8.13
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Daniel Faga
Sector
Healthcare
Industry
Biotechnology
Employees
104
Beta
0.56
Country
US
Piotroski score
6 / 9 (Middling)
Altman Z-score
2.08
www.anaptysbio.com